Heparin to star at House hearings
Events leading up to the distribution of contaminated heparin will be the focus of hearings tentatively scheduled for April 15 by House Energy & Commerce Oversight and Investigations Subcommittee. A week later, FDA Commissioner Andrew von Eschenbach will be asked to provide scenarios for revamping the agency's foreign drug plant inspection program. Seeking an end to the "unsafe" drug import saga, full committee chairman John Dingell, D-Mich., plans action this year on legislation that would assess annual drug import fees of $300 million to pay for inspection of drug imports (1"The Pink Sheet," Aug. 13, 2007, p. 21)
You may also be interested in...
FDA Commissioner Andrew von Eschenbach asked a group of medical products industry representatives July 9 to "think outside the box" to identify role models or lessons learned from other industries that could help address the challenges of drug import safety in a global marketplace
Drug import fees totaling $300 million each in fiscal years 2008 through 2012 would be authorized by a food and drug import safety bill being developed by House Energy and Commerce Committee Chairman John Dingell, D-Mich
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.